Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Survivorship in WM: Identification of Factors Associated with Survival of More Than a Decade and with Early WM-Related Death

Blood (2016) 128 (22): 2954.

https://doi.org/10.1182/blood.V128.22.2954.2954

Published: 2016

Journal Articles

Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: final analysis of a phase 2 study

Efstathios Kastritis, Maria Gavriatopoulou, Marie-Christine Kyrtsonis, Maria Roussou, Evdoxia Hadjiharissi, Argyris Symeonidis, Panagiotis Repoussis, Evridiki Michalis, Sosana Delimpasi, Konstantinos Tsatalas, Panagiotis Tsirigotis, Amalia Vassou, Elina Vervessou, Eirini Katodritou, Dimitra Gika, Evangelos Terpos, Meletios A. Dimopoulos

Blood (2015) 126 (11): 1392–1394.

https://doi.org/10.1182/blood-2015-05-647420

Published: 2015

Includes: Supplemental data

Journal Articles

Safety and Efficacy of Azacitidine in Myelodysplastic Syndrome (MDS) Patients with Mild and Moderate Renal Impairment

Evdoxia Douvali, Menelaos Papoutselis, Emmanuil Spanoudakis, Eleytherios Moustakides, Emilia Tsakiroglou, Konstantinos Tsatalas, Ioannis Kotsianidis, MD, PhD

Blood (2012) 120 (21): 1716.

https://doi.org/10.1182/blood.V120.21.1716.1716

Published: 2012

Journal Articles

The Levels of a G-CSF-Inducible pSTAT3+pSTAT5+ Subpopulation of MDS Progenitors with Leukemic Stem Cell Phenotype Predict the Response to Azacytidine

Paraskevi Miltiades, Eleytheria Labrianidou, Theodoros P. Vassilakopoulos, Sotirios G Papageorgiou, Athanasios G. Galanopoulos, Sofia Vakalopoulou, MD, Ass.Prof.Hematology, Vassilia Garypidou, Evangelia Nakou, Emmanuil Spanoudakis, Maria Papaioannou, Helen A. Papadaki, MD, PhD, Vasiliki Pappa, Konstantinos Tsatalas, Ioannis Kotsianidis, MD, PhD

Blood (2012) 120 (21): 3795.

https://doi.org/10.1182/blood.V120.21.3795.3795

Published: 2012

Journal Articles

Primary Treatment of Waldenstrom's Macroglobulinemia with Dexamethasone, Rituximab and Cyclophosphamide (DRC): Final Analysis of a Phase II Study

Meletios A. Dimopoulos, MD, Maria Roussou, Efstathios Kastritis, Evdoxia Hadjiharissi, Marie-Christine Kyrtsonis, Argiris Symeonidis, MD, PhD, Panagiotis Repoussis, Eurydiki Michalis, Sosana Delimpasi, Konstantinos Tsatalas, Panagiotis Tsirigotis, Amalia Vassou, Elina Vervessou, Eirini Katodritou, Maria Gavriatopoulou, Dimitra Gika, Evangelos Terpos, Konstantinos Zervas

Blood (2012) 120 (21): 438.

https://doi.org/10.1182/blood.V120.21.438.438

Published: 2012

Journal Articles

Determination of the Percentage of CML Patients that Achieve Continuous Complete Molecular Response Under Treatment with TKIs and Are Eligible for Participation in a TKI Discontinuation Study

Blood (2011) 118 (21): 4446.

https://doi.org/10.1182/blood.V118.21.4446.4446

Published: 2011

Journal Articles

No Significant Improvement In the Outcome of Patients with Waldenström's Macroglobulinemia Treated Over the Last 25 Years

Blood (2010) 116 (21): 3032.

https://doi.org/10.1182/blood.V116.21.3032.3032

Published: 2010

Journal Articles

The International Scoring System (ISS) for Multiple Myeloma Remains a Robust Prognostic Tool Independently of Patients' Renal Function

Blood (2010) 116 (21): 3036.

https://doi.org/10.1182/blood.V116.21.3036.3036

Published: 2010

Journal Articles

Alterations In the Signaling Profile of Leukemic Progenitors Can Predict the Response of Myelodysplastic Syndrome (MDS) Patients to Azacytidine

Paraskevi Miltiades, Irene Bouchliou, Evangelia Nakou, Emmanuil Spanoudakis, Sotirios Papageorgiou, Vasiliki Pappa, Maria Papaioannou, Eleytherios Moustakidis, Sofia Vakalopoulou, Vasilia Garipidou, Konstantinos Tsatalas, Ioannis Kotsianidis

Blood (2010) 116 (21): 2921.

https://doi.org/10.1182/blood.V116.21.2921.2921

Published: 2010

Journal Articles

The Combination of the Proteasome Inhibitor Bortezomib with Doxorubicin and Dexamethasone (PAD Regimen) as Front-Line Therapy In Newly Diagnosed, High-Risk Multiple Myeloma: Results of a Phase II Prospective Multicenter Study

Ioannis Baltathakis, Evangelos Terpos, Sosana Delimpasi, Konstantinos Liapis, Fotios Panitsas, Efstathios Kastritis, Anna Christoforidou, Anastasia Pouli, Konstantinos Tsatalas, Meletios A. Dimopoulos, Nikolaos Harhalakis

Blood (2010) 116 (21): 3052.

https://doi.org/10.1182/blood.V116.21.3052.3052

Published: 2010

Journal Articles

The Diagnostic Value of CD1d Expression In Leukemic B-Chronic Lymphoproliferative Disorders (B-CLPDs)

Eleytherios Moustakidis, Emmanuil Spanoudakis, Irene Bouchliou, Evangelia Nakou, Paraskevi Miltiades, asiliki Kotoula, V, Dimitrios Margaritis, George Bourikas, Richard Szydlo, Anastasios Karadimitris, Konstantinos Tsatalas, MD, PhD, Ioannis Kotsianidis, MD, PhD

Blood (2010) 116 (21): 3576.

https://doi.org/10.1182/blood.V116.21.3576.3576

Published: 2010

Journal Articles

Over-Expression of RANKL In Invariant NKT Cells Is Characteristic of Active Myeloma but Not of MGUS or Asymptomatic Myeloma

Emmanouil Spanoudakis, Menelaos Papoutselis, Ioannis Kotsianidis, Evangelos Terpos, Meletios A. Dimopoulos, Ming Hu, PhD, Amin Rahemtulla, MBBS, PhD, FRCP, Dimitrios Margaritis, Georgios Bourikas, Konstantinos Tsatalas, Anastasios Karadimitris

Blood (2010) 116 (21): 4049.

https://doi.org/10.1182/blood.V116.21.4049.4049

Published: 2010

Journal Articles

Dynamics of Telomere Length and Telomerase Activity in Ph 1 -Negative Chronic Myeloproliferative Disorders

Ioanna Bazdiara, Despina Pantelidou, Athanasios Anastasiadis, Vassilios Papadopoulos, Dimitrios Margaritis, Emmanouil Spanoudakis, Georgios Xanthopoulidis, Ioannis Kotsianidis, Anna Christoforidou, Aggelos Goutzouvelidis, Georgios Bourikas, Konstantinos Tsatalas

Blood (2008) 112 (11): 2789.

https://doi.org/10.1182/blood.V112.11.2789.2789

Published: 2008

Journal Articles

The Combination of Bortezomib, Doxorubicin, and Dexamethasone (PAD) Is an Effective Regimen for High Risk, Newly Diagnosed, Patients with Multiple Myeloma, Reduces Bone Resorption and Normalizes Angiopoietin-1 to Angiopoietin-2 Ratio.

Evangelos Terpos, Sosana Delimpasi, Konstantinos Anargyrou, Ioannis Baltathakis, Efstathios Kastritis, Anna Christoforidou, Konstantinos Tsionos, Konstantinos Tsatalas, Emmanuel Nikiforakis, Meletios A. Dimopoulos, Nikolaos Harhalakis

Blood (2007) 110 (11): 3596.

https://doi.org/10.1182/blood.V110.11.3596.3596

Published: 2007

NARROW

Survivorship in WM: Identification of Factors Associated with Survival of More Than a Decade and with Early WM-Related Death

Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: final analysis of a phase 2 study

Safety and Efficacy of Azacitidine in Myelodysplastic Syndrome (MDS) Patients with Mild and Moderate Renal Impairment

The Levels of a G-CSF-Inducible pSTAT3+pSTAT5+ Subpopulation of MDS Progenitors with Leukemic Stem Cell Phenotype Predict the Response to Azacytidine

Primary Treatment of Waldenstrom's Macroglobulinemia with Dexamethasone, Rituximab and Cyclophosphamide (DRC): Final Analysis of a Phase II Study

Determination of the Percentage of CML Patients that Achieve Continuous Complete Molecular Response Under Treatment with TKIs and Are Eligible for Participation in a TKI Discontinuation Study

No Significant Improvement In the Outcome of Patients with Waldenström's Macroglobulinemia Treated Over the Last 25 Years

The International Scoring System (ISS) for Multiple Myeloma Remains a Robust Prognostic Tool Independently of Patients' Renal Function

Alterations In the Signaling Profile of Leukemic Progenitors Can Predict the Response of Myelodysplastic Syndrome (MDS) Patients to Azacytidine

The Combination of the Proteasome Inhibitor Bortezomib with Doxorubicin and Dexamethasone (PAD Regimen) as Front-Line Therapy In Newly Diagnosed, High-Risk Multiple Myeloma: Results of a Phase II Prospective Multicenter Study

The Diagnostic Value of CD1d Expression In Leukemic B-Chronic Lymphoproliferative Disorders (B-CLPDs)

Over-Expression of RANKL In Invariant NKT Cells Is Characteristic of Active Myeloma but Not of MGUS or Asymptomatic Myeloma

Dynamics of Telomere Length and Telomerase Activity in Ph 1 -Negative Chronic Myeloproliferative Disorders

The Combination of Bortezomib, Doxorubicin, and Dexamethasone (PAD) Is an Effective Regimen for High Risk, Newly Diagnosed, Patients with Multiple Myeloma, Reduces Bone Resorption and Normalizes Angiopoietin-1 to Angiopoietin-2 Ratio.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only